Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

An additional rituximab dose in patients with pemphigus and at least one predictor of relapse may reduce the relapse rate, according to the results of a multicenter French study.

David Rubenstein, Co-Founder and Co-Chairman of The Carlyle Group; Ken Griffin, Founder and CEO of Citadel; Penny Pritzker, former U.S. Commerce Secretary; and Henry Kravis, ...